within Pharmacolibrary.Drugs.ATC.C;

model C10AB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.96,
    Cl             = 7.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.022500000000000003,
    Tlag           = 540
  );

  annotation(Documentation(
    info ="<html><body><p>Bezafibrate is a lipid-lowering agent belonging to the fibrate class, used for the treatment of hyperlipidemia and hypertriglyceridemia. It acts as a peroxisome proliferator-activated receptor (PPAR) agonist, reducing cholesterol and triglyceride levels. Bezafibrate is approved and used clinically for the management of dyslipidemia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Cadorniga, R, et al., &amp; Iglesias, JJ (1991). Comparative pharmacokinetics of two oral bezafibrate preparations. <i>European journal of drug metabolism and pharmacokinetics</i> Spec No 3 261–267. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1820889/&quot;>https://pubmed.ncbi.nlm.nih.gov/1820889</a></p></li><li><p>Ledermann, H, &amp; Kaufmann, B (1981). Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form. <i>The Journal of international medical research</i> 9(6) 516–520. DOI:<a href=&quot;https://doi.org/10.1177/030006058100900616&quot;>10.1177/030006058100900616</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7319135/&quot;>https://pubmed.ncbi.nlm.nih.gov/7319135</a></p></li><li><p>Sun, R, et al., &amp; Yousaf, AM (2020). Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate. <i>International journal of nanomedicine</i> 15 705–715. DOI:<a href=&quot;https://doi.org/10.2147/IJN.S235146&quot;>10.2147/IJN.S235146</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32099359/&quot;>https://pubmed.ncbi.nlm.nih.gov/32099359</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C10AB02;
